Education
About Us
Working with TipRanks
Follow Us
Beam Therapeutics (BEAM)
NASDAQ:BEAM
BEAM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$17.16 - $35.25
Previous CloseN/A
Volume491.48K
Average Volume (3M)2.31M
Market Cap
$1.76B
Enterprise Value$1.36B
Total Cash (Recent Filing)-$1.90M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.30
Next Earnings
May 13, 2025EPS Estimate
-1.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.58
Shares Outstanding99,839,980
10 Day Avg. Volume2,504,477
30 Day Avg. Volume2,309,171
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)30.70
Price to Cash Flow (P/CF)-6.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit21.49
Enterprise Value/Ebitda-3.55
Forecast
1Y Price Target
$45.83Price Target Upside148.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
---
Bulls Say, Bears Say
Bulls Say
Clinical DataThe recent data for BEAM-302 is seen as a key value unlocking event, making Beam's platform increasingly derisked with an attractive valuation.
Financial PositionThe $1.35 billion cash position provides Beam Therapeutics with a strong financial runway into 2028, sufficient to advance current therapies into late-stage studies.
Market OpportunityThe market for AATD is projected to be a significant opportunity with over $5 billion in peak sales.
Bears Say
Investment RiskA lack of clinical binaries in the near term is identified as the biggest risk to the investment thesis.
Regulatory ChallengesRegulatory: Highly uncertain. Dr. Rennard thinks it may be 'overly optimistic' to think FDA will apply the 11 micromolar approval bar to novel modalities.
---
Ownership Overview
26.97% Insiders
16.69% Mutual Funds
0.09% Other Institutional Investors
31.74% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BEAM FAQ
What was Beam Therapeutics’s price range in the past 12 months?
Beam Therapeutics lowest stock price was $17.16 and its highest was $35.25 in the past 12 months.
What is Beam Therapeutics’s market cap?
Beam Therapeutics’s market cap is $1.76B.
When is Beam Therapeutics’s upcoming earnings report date?
Beam Therapeutics’s upcoming earnings report date is May 13, 2025 which is in 39 days.
How were Beam Therapeutics’s earnings last quarter?
Beam Therapeutics released its earnings results on Feb 25, 2025. The company reported -$1.09 earnings per share for the quarter, beating the consensus estimate of -$1.228 by $0.138.
Is Beam Therapeutics overvalued?
According to Wall Street analysts Beam Therapeutics’s price is currently Undervalued.
Does Beam Therapeutics pay dividends?
Beam Therapeutics does not currently pay dividends.
What is Beam Therapeutics’s EPS estimate?
Beam Therapeutics’s EPS estimate is -1.19.
How many shares outstanding does Beam Therapeutics have?
Beam Therapeutics has 99,839,980 shares outstanding.
What happened to Beam Therapeutics’s price movement after its last earnings report?
Beam Therapeutics reported an EPS of -$1.09 in its last earnings report, beating expectations of -$1.228. Following the earnings report the stock price went down -3.085%.
Which hedge fund is a major shareholder of Beam Therapeutics?
Currently, no hedge funds are holding shares in BEAM
---
Beam Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$45.83 (148.00% Upside)
$45.83 (148.00% Upside)
Blogger Sentiment
Bullish
BEAM Sentiment 71%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 852.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.50%
12-Months-Change
Fundamentals
Return on Equity
-43.94%
Trailing 12-Months
Asset Growth
-24.38%
Trailing 12-Months
Company Description
Beam Therapeutics
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
---
BEAM Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of significant advancements in Beam's clinical programs, particularly in sickle cell disease and liver genetic diseases, alongside notable challenges related to patient safety in ongoing trials. While the progress in clinical data and technology development is promising, the safety concerns related to conditioning agents are a critical issue.Read More>---
BEAM Stock 12 Month Forecast
Average Price Target
$45.83
▲(148.00% Upside)
Technical Analysis
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Replimune Group
―
Verve Therapeutics
―
Best Analysts Covering BEAM
1 Year
1 Year Success Rate
5/14 ratings generated profit
1 Year Average Return
-12.18%
reiterated a buy rating 14 days ago
Copying Yanan Zhu's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of -12.18% per trade.
---